March 20, 2017
Ab Science in phase 3 of amytrophic lateral sclerosis treatment
AB Science pharmaceutical company, specialist in the protein kinase inhibitors (PKIs), said on Monday that it had the first successful phase 3 trial of a tyrosine kinase inhibitor in the treatment of amyotrophic lateral sclerosis (ALS).